Working… Menu
Trial record 1 of 1 for:    CA180-399
Previous Study | Return to List | Next Study

Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01593254
Recruitment Status : Active, not recruiting
First Posted : May 8, 2012
Results First Posted : April 11, 2019
Last Update Posted : April 11, 2019
ICON Clinical Research
Molecular MD
Q2 Solutions
Donald E. Morisky
MD Anderson Symptom Inventory (MDASI-CML)
OBiS, Inc
Steering Committee
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The purpose of this study is to test the hypothesis that patients with CML who have not achieved optimal response after 3 months of treatment with imatinib will have a better response by switching to dasatinib compared to staying on their original imatinib regimen.

Condition or disease Intervention/treatment Phase
Chronic Phase Chronic Myeloid Leukemia Drug: Imatinib Drug: Dasatinib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 262 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg Imatinib
Actual Study Start Date : October 29, 2012
Actual Primary Completion Date : November 8, 2017
Estimated Study Completion Date : February 17, 2022

Arm Intervention/treatment
Active Comparator: Arm 1: Imatinib (≥400 mg)
Imatinib ≥400 mg tablets by mouth once daily (QD) or twice daily (BID) up to 60 months
Drug: Imatinib
Other Names:
  • Gleevec
  • Glivec

Active Comparator: Arm 2: Dasatinib (100 mg)
Dasatinib 100 mg tablet by mouth QD up to 60 months
Drug: Dasatinib
Other Name: Sprycel

Primary Outcome Measures :
  1. Percentage of Patients Achieving Major Molecular Response (MMR) After 12 Months of CML Treatment [ Time Frame: At 12 months after Day 1 initiation of 1st line treatment with imatinib or imatinib at any dose, after less than optimal response to first-line imatinib. ]

    Major Molecular Response, is defined as a 3-log reduction in BCR-ABL transcripts from the standardized baseline, which represents 100% on the international scale, so a 3-log reduction is fixed at 0.1% for MMR; N/A = not applicable. 95% CI is Clopper-Pearson(Exact) two-sided 95% confidence intervals.

    P-value is based on Cochran-Mantel-Haenszel (CMH) test stratified by Sokal score(high, intermediate, low, and unknown) and time between 3 month molecular analysis and randomization (<=4 weeks vs >4 weeks). Month 12 is calculated fro

Secondary Outcome Measures :
  1. Median Time to Major Molecular Response (MMR) [ Time Frame: Up to 10 years ]
    Time to MMR is how fast patients achieve optimal response. It is the time between randomization date and first date that MMR criteria are satisfied.

  2. Time to Molecular Response (MR)^4.5 [ Time Frame: Up to 10 years ]
    Time to MR^4.5 is how fast patients achieve a deeper response. It is the time between randomization date and first date that MR^4.5 criteria are satisfied.

  3. Progression Free Survival (PFS) [ Time Frame: Up to 10 years ]
    PFS is how long patients are likely to live without progression of their disease. It is the time from randomization date to progression date or death date, whichever occurs first.

  4. Overall Survival (OS) [ Time Frame: Up to 10 years ]
    OS is how long patients are likely to remain alive. It is the time from randomization date to death date.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

  • Chronic Phase (CP)-CML Ph+ patients with complete hematologic response (CHR) but without one log BCR-ABL reduction (BCR-ABL level >10% IS) 3 months of imatinib 400mg treatment. (Imatinib transient dose adjustments due to Adverse Event (AEs) are allowed with a maximum of 2 weeks interruption of treatment with imatinib (cumulative) within the 3 month period before randomization). Imatinib monotherapy must have been started within 6 months of CP-CML diagnosis (Ph + /BCR-ABL detection)
  • Currently tolerating imatinib 400mg QD. Patients with prior imatinib treatment interruption or dose reductions are required to be on treatment with 400 mg imatinib for two weeks immediately prior to randomization to ensure tolerance to imatinib
  • Eastern Co-Operative Group (ECOG) performance status = 0 - 2
  • Adequate renal function defined as serum creatinine ≤3 times the institutional upper limit of normal (ULN)
  • Adequate hepatic function defined as: total bilirubin ≤2.0 times the institutional ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times the institutional ULN

Exclusion Criteria:

  • Previous diagnosis of accelerated phase or blast crisis
  • Subjects with clonal evolution in Ph+ cells observed in ≥2 metaphases at baseline bone marrow cytogenetic test, unless the same abnormalities were present at diagnosis. Patients with no evidence of clonal evolution, including those patients whose cytogenetic testing fails or bone marrow aspiration is a dry tap at 3 months, are eligible for the study
  • Subjects with less than CHR after 3 months of imatinib treatment or lost CHR after initial achievement
  • Documented T315I/A, F317L, or V299L mutations (if already available - not required for screening)
  • A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01593254

  Hide Study Locations
Layout table for location information
United States, California
Pacific Cancer Medical Center, Inc.
Anaheim, California, United States, 92801
Kaiser Permanente Medical Center_Fontana
Fontana, California, United States, 92335
University Of Southern California University Hospital
Los Angeles, California, United States, 90033
Kaiser Permanente Medical Center
Oakland, California, United States, 94611
Kaiser Permanente Oncology Clinical Trials
Vallejo, California, United States, 94589-2441
Innovative Clinical Research Institute
Whittier, California, United States, 90603
United States, Connecticut
Cancer Center of Central Connecticut
Southington, Connecticut, United States, 06489
United States, Illinois
Northwestern University
Evanston, Illinois, United States, 60208
Carle Cancer Center
Urbana, Illinois, United States, 61801
United States, Indiana
Franciscan St. Francis Health
Indianapolis, Indiana, United States, 46237
Northern Indiana Cancer Research Consortium
South Bend, Indiana, United States, 46628
United States, Iowa
University Of Iowa
Iowa City, Iowa, United States, 52242
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Ohio
Oncology Hematology Care
Cincinnati, Ohio, United States, 45242
United States, Pennsylvania
Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 1522
United States, Tennessee
Tennesssee Oncology - Centennial Clinic Location
Nashville, Tennessee, United States, 37203
United States, Texas
Michael E Debakey VAMC
Houston, Texas, United States, 77030
Institute of Oncology Hematology Biomedical Research
Laredo, Texas, United States, 78041
United States, West Virginia
Edwards Comprehensive Cancer Center
Huntington, West Virginia, United States, 25701
United States, Wisconsin
Froedtert & Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Local Institution
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, 1425
Local Institution
La Plata, Buenos Aires, Argentina
Local Institution
Ramos Mejia, Buenos Aires, Argentina, 1221
Local Institution
Corrientas, Provincia DE Corientas, Argentina, CP3400
Local Institution
San Miguel de Tucuman, Tucuman, Argentina, 4000
Local Institution
Buenos Aires, Argentina, C1114AAN
Local Institution
Furstenfeld, Austria, 8280
Local Institution
Graz, Austria, 8036
Local Institution
Innsbruck, Austria, 6020
Local Institution
Linz, Austria
Local Institution
Wels, Austria, 4600
Local Institution
Wien, Austria, 1090 Wien
Local Institution
Brugge, Belgium, B-8000
Local Institution
Merksem, Belgium, 2170
Local Institution
Yvoir, Belgium, 5530
Local Institution
Goiania, Goias, Brazil, 74605-020
Local Institution
Curitiba, Parana, Brazil, 80060-900
Local Institution
Campinas, SAO Paulo, Brazil, 13083-970
Local Institution
Ribeir?o Preto, SAO Paulo, Brazil, 14048-900
Local Institution
Rio de Janeiro, Brazil, 20211-030
Local Institution
Rio de Janeiro, Brazil, 20231-050
Local Institution
Sao Paulo, Brazil, 08270-070
Canada, New Brunswick
Local Institution
Saint John, New Brunswick, Canada, E2L 4L2
China, Beijing
Local Institution
Beijing, Beijing, China, 100034
Local Institution
Beijing, Beijing, China, 100071
China, Fujian
Local Institution
Fuzhou, Fujian, China, 350001
China, Guangdong
Local Institution
Guangzhou, Guangdong, China, 510080
Local Institution
Guangzhou, Guangdong, China, 510515
China, Heilongjiang
Local Institution
Haerbin, Heilongjiang, China, 150010
China, Hubei
Local Institution
Wuhan, Hubei, China, 430022
Local Institution
Wuhan, Hubei, China, 430030
China, Jiangsu
Local Institution
Nanjing, Jiangsu, China, 210029
Local Institution
Suzhou, Jiangsu, China, 215000
China, Liaoning
Local Institution
Shenyang, Liaoning, China, 110001
China, Shan3xi
Local Institution
Xian, Shan3xi, China, 710000
China, Shanghai
Local Institution
Xian, Shanghai, China, 200025
China, Sichuan
Local Institution
Chengdu, Sichuan, China, 610041
China, Tianjin
Local Institution
Tianjin, Tianjin, China, 300020
Local Institution
Hangzhou, China, 310003
Local Institution
Jinan, China, 250012
Local Institution
Shenzhen, China, 518035
Local Institution
Brno, Czechia, 625 00
Local Institution
Hradec Kralove, Czechia, 500 05
Local Institution
Olomouc, Czechia, 775 20
Local Institution
Prague 10, Czechia, 100 34
Local Institution
Prague 2, Czechia, 12808
Local Institution
Le Chesnay Cedex, France, 78157
Local Institution
Lille cedex, France, 59037
Local Institution
Nantes, France, 44000
Local Institution
Pierre Benite cedex, France, 69495
Local Institution
Vandoeuvre-les-Nancy Cedex, France, 54511
Local Institution
Budapest, Hungary, 1083
Local Institution
Szeged, Hungary, H-6720
Local Institution
Bari, Italy, 70124
Local Institution
Bologna, Italy, 40138
Local Institution
Brescia, Italy, 25123
Local Institution
Catania, Italy, 95124
Local Institution
Firenze, Italy, 50134
Local Institution
Monza, Italy, 20900
Local Institution
Napoli, Italy, 80131
Local Institution
Orbassano, Italy, 10043
Local Institution
Roma, Italy, 00144
Local Institution
Roma, Italy, 00161
Korea, Republic of
Local Institution
Seoul, Korea, Republic of, 06351
Local Institution
Seoul, Korea, Republic of, 137-701
Local Institution
Seoul, Korea, Republic of, 138-736
Local Institution
Gdansk, Poland, 80-952
Local Institution
Katowice, Poland, 40-032
Local Institution
Krakow, Poland, 30-510
Local Institution
Warszawa, Poland, 02-776
Local Institution
L'Hospitalet Del Llobregat, Spain, 08908
Local Institution
Las Palmas de Gran Canaria, Spain, 35010
Local Institution
Madrid, Spain, 28007
Local Institution
Salamanca, Spain, 37007
Local Institution
Santiago de Compostela, Spain, 15706
Local Institution
Toledo, Spain, 45004
Local Institution
Bangkok, Thailand, 10400
Local Institution
Khon Kaen, Thailand, 40002
Local Institution
Muang, Thailand, 50200
Sponsors and Collaborators
Bristol-Myers Squibb
ICON Clinical Research
Molecular MD
Q2 Solutions
Donald E. Morisky
MD Anderson Symptom Inventory (MDASI-CML)
OBiS, Inc
Steering Committee
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  Study Documents (Full-Text)

Documents provided by Bristol-Myers Squibb:
Study Protocol  [PDF] March 9, 2018
Statistical Analysis Plan  [PDF] March 9, 2018

Additional Information:
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb Identifier: NCT01593254     History of Changes
Other Study ID Numbers: CA180-399
2011-006181-41 ( EudraCT Number )
First Posted: May 8, 2012    Key Record Dates
Results First Posted: April 11, 2019
Last Update Posted: April 11, 2019
Last Verified: March 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Chronic-Phase
Neoplasms by Histologic Type
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action